Beta-catenin–lymphoid enhancer-binding factor 1 complex (β-catenin/LEF1 complex)

The beta-catenin–lymphoid enhancer-binding factor 1 (LEF1) complex is a critical nuclear transcriptional regulator in the canonical Wnt signaling pathway. Upon Wnt pathway activation, beta-catenin accumulates in the cytoplasm and translocates to the nucleus, where it binds to LEF1 (a member of the TCF/LEF family of transcription factors). This complex displaces co-repressors and recruits co-activators to drive expression of Wnt target genes, governing cell proliferation, fate, and differentiation[1][2][3][5]. Aberrant activation of this complex—often through increased nuclear beta-catenin—is a hallmark of several cancers, and thus the interface between beta-catenin and LEF1 is recognized as a therapeutic target in oncology[1][2]. The β-catenin/LEF1 interaction can also influence cell cycle progression and developmental signaling, making its modulation a double-edged sword with both antitumor potential and safety challenges due to its pivotal role in normal physiology[1][2][3].

Other names

β-catenin/LEF-1 interactionBeta-catenin–LEF1 complexBeta-catenin–Lef-1 interactionβ-catenin–lymphoid enhancer-binding factor 1 interaction

Inhibition of β-catenin–LEF1 binding blocks Wnt-driven transcriptional activation of target genes, suppressing proliferation and survival signals in cancer cells. Disruption of nuclear complex formation prevents β-catenin from acting as a transcriptional co-activator for LEF1-dependent genes.